NovoCure Q3 EPS $(0.46) Beats $(0.52) Estimate, Sales $127.32M Miss $128.76M Estimate
Portfolio Pulse from Benzinga Newsdesk
NovoCure (NASDAQ:NVCR) reported Q3 earnings per share of $(0.46), beating the analyst consensus estimate of $(0.52) by 11.54%. However, the company's quarterly sales of $127.32 million missed the analyst consensus estimate of $128.76 million by 1.12%. This represents a 2.81% decrease in sales compared to the same period last year.
October 26, 2023 | 11:01 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
NovoCure's Q3 earnings beat estimates but sales missed, indicating mixed financial performance.
NovoCure's earnings beat estimates, which is a positive signal for investors. However, the company's sales missed estimates, which could be a concern. The mixed results may lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100